Several Houston organizations have received millions from the Cancer Prevention and Research Institute of Texas. Photo via tmc.edu

Three prominent institutions in Houston will be able to snag a trio of high-profile cancer researchers thanks to $12 million in new funding from the Cancer Prevention and Research Institute of Texas.

The biggest recruitment award — $6 million — went to the University of Texas MD Anderson Center to lure researcher Xiling Shen away from the Terasaki Institute for Biomedical Innovation in Los Angeles.

Shen is chief scientific officer at the nonprofit Terasaki Institute. His lab there studies precision medicine, including treatments for cancer, from a “systems biology perspective.”

He also is co-founder and former CEO of Xilis, a Durham, North Carolina-based oncology therapy startup that raised $70 million in series A funding in 2021. Before joining the institute in 2021, the Stanford University graduate was an associate professor at Duke University in Durham.

Shen and Xilis aren’t strangers to MD Anderson.

In 2023, MD Anderson said it planned to use Xilis’ propriety MicroOrganoSphere (MOS) technology for development of novel cancer therapies.

“Our research suggests the MOS platform has the potential to offer new capabilities and to improve the efficiency of developing innovative drugs and cell therapies over current … models, which we hope will bring medicines to patients more quickly,” Shen said in an MD Anderson news release.

Here are the two other Cancer Prevention and Research Institute of Texas (CPRIT) awards that will bring noted cancer researchers to Houston:

  • $4 million to attract David Sarlah to Rice University from the University of Illinois, where he is an associate professor of chemistry. Sarlah’s work includes applying the principles of chemistry to creation of new cancer therapies.
  • $2 million to lure Vishnu Dileep to the Baylor College of Medicine from the Massachusetts Institute of Technology (MIT), where he is a postdoctoral fellow. His work includes the study of cancer genomes.

CPRIT also handed out more than $56.5 million in grants and awards to seven institutions in the Houston area. Here’s the rundown:

  • MD Anderson Cancer Center — Nearly $25.6 million
  • Baylor College of Medicine — Nearly $11.5 million
  • University of Texas Health Science Center at Houston — More than $6 million
  • Rice University — $4 million
  • University of Texas Medical Branch at Galveston — More than $3.5 million
  • Methodist Hospital Research Institute — More than $3.3 million
  • University of Houston — $1.4 million

Dr. Pavan Reddy, a CPRIT scholar who is a professor at the Baylor College of Medicine and director of its Dan L Duncan Comprehensive Cancer Care Center, says the CPRIT funding “will help our investigators take chances and explore bold ideas to make innovative discoveries.”

The Houston-area funding was part of nearly $99 million in grants and awards that CPRIT recently approved.

Houston Methodist's cardiovascular sciences, orthopedics and RNA therapeutics research programs will be the first to occupy the new space. Photo via houstonmethodist.org

Houston Methodist signs on at new TMC Helix Park building

moving in

Texas medical giant Houston Methodist is the latest to join the Dynamic One building within TMC Helix Park.

The hospital announced that it has signed a 75,800-square-foot lease in the building and will take over two floors of biomedical research laboratories. Houston Methodist's cardiovascular sciences, orthopedics and RNA therapeutics research programs will be the first to occupy the space.

“We are always focused on translating innovative medical discoveries into viable therapies for patients. These highly entrepreneurial programs, which translate these discoveries to the bedside, are a natural fit within the emerging biotechnology ecosystem that the TMC is cultivating,” Edward Jones, president and CEO of Houston Methodist Research Institute, said in the announcement.

Houston Methodist joins anchor tenant Baylor College of Medicine in the state-of-the-art building, which opened in Nov. 2023.

The 12-story Dynamic One building features lab space, offices, restaurants, and stores. It represents the first of four buildings planned for the 37-acre TMC Helix Park and was one of the largest life sciences projects in the U.S. set to come online last year.

Developers are slated to open three more move-in-ready Beacon Ready Labs in the building this summer, ranging from 9,000 to 15,000 square feet.

“We are excited to welcome Houston Methodist to this space; their commitment to bench to bedside innovation and track record of transformative new discoveries aligns with our vision for the campus,” William McKeon, president and CEO of the Texas Medical Center, said in a statement. “Beacon Capital has been an outstanding partner in the development of TMC Helix Park, lending their insights to our efforts to design a campus that would seamlessly blend institutions and industry.”

TMC Helix Park officially opened last October with the launch of the TMC3 Collaborative Building. The 250,000-square-foot building anchors the campus and houses research initiatives from the four founding partners: Texas Medical Center, The University of Texas MD Anderson Cancer Center, Texas A&M University Health Science Center, and The University of Texas Health Science Center at Houston.

UTHealth Houston also broke ground on its 350,000-square-foot tower on the campus last summer. It's slated to open in time for the 2026 Fall semester. And TMC unveiled plans for the fourth and final component of Helix Park, the TMC BioPort, in 2022.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort.

TMC names 2024 cohort of cancer treatment innovators

ready to grow

For the fourth year, Texas Medical Center Innovation has named its annual cohort of Texas health tech innovators working on promising cancer therapeutics.

TMCi named its 2024 Accelerator for Cancer Therapeutics cohort last week, and the 23 Texas researchers and companies selected will undergo a nine-month program that will provide them with mentorship and programming, as well as open doors to potential investors and strategic partners.

“The ACT program provides a bridge to commercialization in Texas by surrounding innovators with strategic mentorship, milestone development, and a network of resources to move their projects forward,” Emily Reiser, associate director of TMC Innovation, says in a news release. "We are excited to welcome this year's cohort and to continue enabling participants to advance their solutions to treat cancer."

The program has accelerated 76 researchers and companies to date, many of which — like March Biosciences and Mongoose Bio — have gone on to secure $130 million in funding from venture capitalists and grant funding.

“Our program has cultivated a dynamic ecosystem where partners, researchers, and inventors, who have been part of the journey since its inception and received various forms of funding, continue to propel their life-saving products and technologies forward," Ahmed AlRawi, program manager of ACT, says in the release. "Our 2024 cohort represents our most diverse cohort to date, including eight companies led by women entrepreneurs. Additionally, we are particularly proud that the cohort includes a blend of new and recurring organizations that have leveraged this opportunity in the past to extend their work and continue the momentum to build off the successes of our previous years.”

The 2024 participants are:

  • Alexandre Reuben of UT-MD Anderson Cancer Center
  • Betty Kim & Jiang Wen of UT-MD Anderson Cancer Center
  • Bin He of Houston Methodist
  • Daniel Kiss & John Cooke of PeakRNA at Houston Methodist
  • Hongjun Liang of Texas Tech-Lubbock
  • Jacob Goell & Isaac Hilton of Mercator Biosciences at Rice University
  • Jay Hartenbach & Matthew Halpert of Diakonos Oncology Corp.
  • Kathryn O’Donnell of UT-Southwestern
  • Maralice Conacci Sorrell of UT-Southwestern
  • Neeraj Saini of UT-MD Anderson Cancer Center
  • Neil Thapar of Barricade Therapeutics Corp.
  • Nina Keshavarzi of Celine Biotechnologies
  • Raphael G. Ognar & Henri Bayle of NKILT Therapeutics Inc.
  • Richard Austin & Michael Abrahamson of Reglagene Inc.
  • Tim Peterson & Joppe Nieuwenhuis of Bioio Inc.
  • Todd Aguilera & Eslam Elghonaimy of UT-Southwestern
  • Venkata Lokesh Battula of Siddhi Therapeutics Inc. at UT-MD Anderson Cancer Center
  • Weei-Chin Lin & Fang-Tsyr Lin of Baylor College of Medicine
  • Yong Li & Dongxiao Feng of Sotla Therapeutics at Baylor College of Medicine
  • Anil Sood & Zhiqiang An of UT-MD Anderson Cancer Center
  • Narendra Kumar & Jayshree Mishra of Texas A&M-College Station
  • Tao Wang of NightStar Biotechnologies Inc. at UT-Southwestern
  • Jian Hu of UT-MD Anderson Cancer Center
This week's roundup of Houston innovators includes Sunny Zhang of TrueLeap, Jim Dillon of BiVACOR, and Livia Schiavinato Eberlin of Baylor College of Medicine. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Each week, I'm introducing you to three Houston innovators to know — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Sunny Zhang, founder of TrueLeap

Sunny Zhang joins the Houston Innovators Podcast. Photo via LinkedIn

It's safe to say Sunny Zhang has a handle on the machine and cycle that innovation as a tenured business professor, startup founder, and venture capital investor. An academic at her core, she looks at innovation from the outside in — and inside out — in her various roles.

But there is a throughline for Zhang, and it's observing the innovation cycle. In her 20 years, she's worked closely with startups on the topic.

"My research has always focused on the innovation diffusion process — essentially the psychological and behavioral science of innovation diffusion when a product is introduced in a marketplace. How is that adoption going in a network as a result in many factors — internally and externally in a digital world and in the international and global market," Zhang says on the Houston Innovators Podcast.

"I've been seeing how innovation works, how products are getting adopted, and the behavioral process in it. We talk about 'go-to market,' but I want to promote 'come-from market.' Identify the problem itself," Zhang says, explaining that as both an academic and life-long learner, this is important to her.

Jim Dillon, CEO of BiVACOR

Jim Dillon has been named CEO of BiVACOR. Photo courtesy of BiVACOR

Houston-based medical device company BiVACOR has brought aboard a new CEO.

Jim Dillon, a longtime executive in the medical device sector, has been hired to lead BiVACOR and join its board of directors. Dillon succeeds former heart surgeon Dr. Thomas Vassiliades, whose appointment as CEO was announced in January 2022.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Raymond Cohen, chairman of BiVACOR, says in a news release. Continue reading.

Livia Schiavinato Eberlin, associate professor of surgery at Baylor College of Medicine

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research. Photo via bcm.edu

An associate professor of surgery at Baylor College of Medicine has won a prestigious award for young chemical scientists in the state and secured $3 million in funding to further develop her technology.

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research in December. The award was established by the Houston-based Welch Foundation and recognizes the accomplishments of chemical scientists in Texas who are early in their careers. Eberlin will be granted $100,000 for this honor.

Eberlin runs the Eberlin Lab for Medical Mass Spectrometry at BCM and is known for her groundbreaking work in the application of mass spectrometry technologies, which are changing how physicians treat cancer and analyze tissues.

In the same week, Baylor College of Medicine announced that the Eberlin Lab received $3 million in funding from The Marcus Foundation to further develop the MasSpec Pen technology in breast cancer surgeries. Eberlin developed the tool in 2016 while she was serving as an assistant professor at the University of Texas at Austin. The MasSpec Pen is a device for detecting cancer directly on tissues. Continue reading.

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research. Photo via bcm.edu

Baylor scientist wins award for young chemists, scores $3M for groundbreaking cancer tech

on the rise

An associate professor of surgery at Baylor College of Medicine has won a prestigious award for young chemical scientists in the state and secured $3 million in funding to further develop her technology.

Livia Schiavinato Eberlin was named the 2024 recipient of the Norman Hackerman Award in Chemical Research in December. The award was established by the Houston-based Welch Foundation and recognizes the accomplishments of chemical scientists in Texas who are early in their careers. Eberlin will be granted $100,000 for this honor.

Eberlin runs the Eberlin Lab for Medical Mass Spectrometry at BCM and is known for her groundbreaking work in the application of mass spectrometry technologies, which are changing how physicians treat cancer and analyze tissues.

“I firmly believe that Dr. Eberlin’s commitment to transformational chemical research is unparalleled, and her impressive growth over her early independent career points to a bright future of scientific discoveries that will continue to revolutionize the field of chemical and biomedical research and improve treatment for patients,” Dr. Todd Rosengart, chair of Surgery at the Baylor College of Medicine and faculty adviser to Dr. Eberlin, says in a statement. “She is highly deserving of this honor.”

In the same week, Baylor College of Medicine announced that the Eberlin Lab received $3 million in funding from The Marcus Foundation to further develop the MasSpec Pen technology in breast cancer surgeries. Eberlin developed the tool in 2016 while she was serving as an assistant professor at the University of Texas at Austin. The MasSpec Pen is a device for detecting cancer directly on tissues.

“When I met Dr. Eberlin and understood how the MasSpec Pen could help surgeons and ultimately impact patient lives, it was an easy yes to support the expansion of this innovative tool. It’s absolutely brilliant technology,” says Bernie Marcus, chairman of The Marcus Foundation and co-founder of The Home Depot, in a BCM news release.

The technology is being used in clinical studies at the Texas Medical Center to detect cancer tissue during a surgical operation, which allows doctors to more accurately remove tumor tissue. The fresh funding will help enroll 200 patients at two Houston hospitals: Ben Taub Hospital and Baylor St. Luke’s Medical Center.

The Eberlin Lab at BCM is also researching ways to provide physicians with better, real-time decision-making tools to help with cancer diagnosis, disease progression, prognosis and treatment strategies, according to BCM.

“The strides Dr. Eberlin has made in her career so far are beyond commendable and make her an ideal choice for the Hackerman Award,” Douglas L. Foshee, director and chair of The Welch Foundation, said in a statement. “Her creative and hardworking nature is fundamentally changing the treatment experience for patients with cancer, not to mention the field of chemistry as a whole.”

Eberlin is originally from Campinas, São Paulo, Brazil, where she earned her undergraduate degree from State University of Campinas. She obtained her graduate degree from Purdue University and a Ph.D. in Analytical Chemistry from Stanford University. In addition to the award from the Welch foundation, she has also received several other prestigious honors, including a Sloan Research Fellowship, Moore Inventor Fellowship, and a MacArthur Fellowship in 2018.

The Welch Foundation has contributed close to $1.1 billion to scientists in Texas since it was founded in 1954. Earlier this year it funded the Welch Center for Advanced Bioactive Materials Crystallization at the University of Houston through its inaugural $5 million Catalyst for Discovery Program Grant.

The nonprofit organization also announced nearly $28 million in grants to Texas institutions over the summer.

The Center for Innovation and Translation of POC Technologies for Equitable Cancer Care, or CITEC, will be managed through Rice360 Institute for Global Health Technologies. Photo via Getty Images

Rice-led initiative looks to make cancer detection affordable, equitable

future of health care

A new initiative from two Houston organizations is hoping to develop affordable health care innovation for early cancer detection.

The Center for Innovation and Translation of POC Technologies for Equitable Cancer Care, or CITEC, will be managed through Rice360 Institute for Global Health Technologies, which is part of an ongoing international effort to prepare the future global health workforce.

Rice will be joined by Baylor College of Medicine, University of Texas MD Anderson Cancer Center, University of Sao Paulo, Barretos Cancer Hospital in Brazil, Mozambique Ministry of Health, and Universidade Eduardo Mondlane in Maputo, Mozambique.

“While early detection and treatment of cancer can improve survival, available tests for early cancer detection are too complex or too expensive for hospitals and clinics in medically underserved areas,” CITEC co-principal investigator Rebecca Richards-Kortum, a Rice bioengineering professor and director of Rice360, says in a news release.

The project is part of a five-year grant from the National Institutes of Health to launch a top-tier research center in the Texas Medical Center to develop point-of-care technologies that improve early cancer detection in low-resource in America and internationally that are effective and affordable. Rice’s leading collaboration group to help secure the grant includes engineers, oncologists and international global health partners from three continents. in low-resource settings in the United States and other countries.

CITEC will aim to target development of POC tests for oral, cervical and gastrointestinal cancers through the first-year grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of $1.3 million—up to $6.5 million over five years. CITEC is funded by a NIBIB grant.

Last month, NIBIB announced that CITEC will be one of six research centers that it will support, along with an additional center, through its Point of Care Technology Research Network (POCTRN).

Dr. Sharmila Anandasabapathy, vice president of global health at Baylor College of Medicine, and Tomasz Tkaczyk, bioengineering professor at Rice, are the other two cco-principals on the initiative.

“CITEC will identify needed technologies, accelerate their development, evaluate their performance and impact in diverse settings and train local users and technology developers to create and disseminate more equitable POC technologies,” Anandasabapathy says in the release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

New Houston venture studio emerges to target early-stage hardtech, energy transition startups

funding the future

The way Doug Lee looks at it, there are two areas within the energy transition attracting capital. With his new venture studio, he hopes to target an often overlooked area that's critical for driving forward net-zero goals.

Lee describes investment activity taking place in the digital and software world — early stage technology that's looking to make the industry smarter. But, on the other end of the spectrum, investment activity can be found on massive infrastructure projects.

While both areas need funding, Lee has started his new venture studio, Flathead Forge, to target early-stage hardtech technologies.

“We are really getting at the early stage companies that are trying to develop technologies at the intersection of legacy industries that we believe can become more sustainable and the energy transition — where we are going. It’s not an ‘if’ or ‘or’ — we believe these things intersect,” he tells EnergyCapital.

Specifically, Lee's expertise is within the water and industrial gas space. For around 15 years, he's made investments in this area, which he describes as crucial to the energy transition.

“Almost every energy transition technology that you can point to has some critical dependency on water or gas,” he says. “We believe that if we don’t solve for those things, the other projects won’t survive.”

Lee, and his brother, Dave, are evolving their family office to adopt a venture studio model. They also sold off Azoto Energy, a Canadian oilfield nitrogen cryogenic services business, in December.

“We ourselves are going through a transition like our energy is going through a transition,” he says. “We are transitioning into a single family office into a venture studio. By doing so, we want to focus all of our access and resources into this focus.”

At this point, Flathead Forge has seven portfolio companies and around 15 corporations they are working with to identify their needs and potential opportunities. Lee says he's gearing up to secure a $100 million fund.

Flathead also has 40 advisers and mentors, which Lee calls sherpas — a nod to the Flathead Valley region in Montana, which inspired the firm's name.

“We’re going to help you carry up, we’re going to tie ourselves to the same rope as you, and if you fall off the mountain, we’re falling off with you,” Lee says of his hands-on approach, which he says sets Flathead apart from other studios.

Another thing that's differentiating Flathead Forge from its competition — it's dedication to giving back.

“We’ve set aside a quarter of our carried interest for scholarships and grants,” Lee says.

The funds will go to scholarships for future engineers interested in the energy transition, as well as grants for researchers studying high-potential technologies.

“We’re putting our own money where our mouth is,” Lee says of his thesis for Flathead Forge.

------

This article originally ran on EnergyCapital.

Houston-based lunar mission's rocky landing and what it means for America's return to the moon

houston, we have a problem

A private U.S. lunar lander tipped over at touchdown and ended up on its side near the moon’s south pole, hampering communications, company officials said Friday.

Intuitive Machines initially believed its six-footed lander, Odysseus, was upright after Thursday's touchdown. But CEO Steve Altemus said Friday the craft “caught a foot in the surface," falling onto its side and, quite possibly, leaning against a rock. He said it was coming in too fast and may have snapped a leg.

“So far, we have quite a bit of operational capability even though we’re tipped over," he told reporters.

But some antennas were pointed toward the surface, limiting flight controllers' ability to get data down, Altemus said. The antennas were stationed high on the 14-foot (4.3-meter) lander to facilitate communications at the hilly, cratered and shadowed south polar region.

Odysseus — the first U.S. lander in more than 50 years — is thought to be within a few miles (kilometers) of its intended landing site near the Malapert A crater, less than 200 miles (300 kilometers) from the south pole. NASA, the main customer, wanted to get as close as possible to the pole to scout out the area before astronauts show up later this decade.

NASA's Lunar Reconnaissance Orbiter will attempt to pinpoint the lander's location, as it flies overhead this weekend.

With Thursday’s touchdown, Intuitive Machines became the first private business to pull off a moon landing, a feat previously achieved by only five countries. Japan was the latest country to score a landing, but its lander also ended up on its side last month.

Odysseus' mission was sponsored in large part by NASA, whose experiments were on board. NASA paid $118 million for the delivery under a program meant to jump-start the lunar economy.

One of the NASA experiments was pressed into service when the lander's navigation system did not kick in. Intuitive Machines caught the problem in advance when it tried to use its lasers to improve the lander's orbit. Otherwise, flight controllers would not have discovered the failure until it was too late, just five minutes before touchdown.

“Serendipity is absolutely the right word,” mission director Tim Crain said.

It turns out that a switch was not flipped before flight, preventing the system's activation in space.

Launched last week from Florida, Odysseus took an extra lap around the moon Thursday to allow time for the last-minute switch to NASA's laser system, which saved the day, officials noted.

Another experiment, a cube with four cameras, was supposed to pop off 30 seconds before touchdown to capture pictures of Odysseus’ landing. But Embry-Riddle Aeronautical University’s EagleCam was deliberately powered off during the final descent because of the navigation switch and stayed attached to the lander.

Embry-Riddle's Troy Henderson said his team will try to release EagleCam in the coming days, so it can photograph the lander from roughly 26 feet (8 meters) away.

"Getting that final picture of the lander on the surface is still an incredibly important task for us,” Henderson told The Associated Press.

Intuitive Machines anticipates just another week of operations on the moon for the solar-powered lander — nine or 10 days at most — before lunar nightfall hits.

The company was the second business to aim for the moon under NASA's commercial lunar services program. Last month, Pittsburgh's Astrobotic Technology gave it a shot, but a fuel leak on the lander cut the mission short and the craft ended up crashing back to Earth.

Until Thursday, the U.S. had not landed on the moon since Apollo 17's Gene Cernan and Harrison Schmitt closed out NASA's famed moon-landing program in December 1972. NASA's new effort to return astronauts to the moon is named Artemis after Apollo's mythological twin sister. The first Artemis crew landing is planned for 2026 at the earliest.

3 female Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.

Emma Konet, co-founder and CTO of Tierra Climate

Emma Konet, co-founder and CTO of Tierra Climate, joins the Houston Innovators Podcast. Photo via LinkedIn

If the energy transition is going to be successful, the energy storage space needs to be equipped to support both the increased volume of energy needed and new energies. And Emma Konet and her software company, Tierra Climate, are targeting one part of the equation: the market.

"To me, it's very clear that we need to build a lot of energy storage in order to transition the grid," Konet says on the Houston Innovators Podcast. "The problems that I saw were really on the market side of things." Read more.

Cindy Taff, CEO of Sage Geosystems

Houston-based Sage Geosystems announced the first close of $17 million round led by Chesapeake Energy Corp. Photo courtesy of Sage

A Houston geothermal startup has announced the close of its series A round of funding.

Houston-based Sage Geosystems announced the first close of $17 million round led by Chesapeake Energy Corp. The proceeds aim to fund its first commercial geopressured geothermal system facility, which will be built in Texas in Q4 of 2024. According to the company, the facility will be the first of its kind.

“The first close of our Series A funding and our commercial facility are significant milestones in our mission to make geopressured geothermal system technologies a reality,” Cindy Taff, CEO of Sage Geosystems, says. Read more.

Clemmie Martin, chief of staff at The Cannon

With seven locations across the Houston area, The Cannon's digital technology allows its members a streamlined connection. Photo courtesy of The Cannon

After collaborating over the years, The Cannon has acquired a Houston startup's digital platform technology to become a "physical-digital hybrid" community.

Village Insights, a Houston startup, worked with The Cannon to create and launch its digital community platform Cannon Connect. Now, The Cannon has officially acquired the business. The terms of the deal were not disclosed.

“The integration of a world-class onsite member experience and Cannon Connect’s superior virtual resource network creates a seamless, streamlined environment for member organizations,” Clemmie Martin, The Cannon’s newly appointed chief of staff, says in the release. “Cannon Connect and this acquisition have paved new pathways to access and success for all.” Read more.